Serazide

Benserazide An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.

[1. An l-aromatic amino acid decarboxylase (dopa decarboxylase) inhibitor resembling carbidopa in action; given in combination with levodopa as an antiparkinsonian regimen. The benserazide prevents peripheral destruction of levodopa and thus reduces cardiovascular side effects of treatment.

Molecular Formula: C₁₀H₁₅N₃O₅

InChI: InChI=1/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)/f/h13H

InChIKey: InChIKey=BNQDCRGUHNALGH-NDKGDYFDCE
SMILES: C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O

Names:
    Benserazida [INN-Spanish]
    Benserazide [USAN:BAN:INN]
    benserazide
    Benserazidum [INN-Latin]
    BRN 3984490
    DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide
    DL-Seryltrihydroxybenzylhydrazine
    Madopa
    Ro 4-4602
    Serazide
    2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide

Registries:
    PubChem CID 2327
    PubChem ID 152671